The standard treatment for muscle-invasive urothelial carcinoma (MIUC) has been radical surgery combined with cisplatin-based chemotherapy for eligible patients. However, over 50% of patients face metastatic progression after surgery. This non-CME webinar, presented by a urology expert, will discuss how patients with UC at high risk of recurrence after radical resection may benefit from adjuvant immunotherapy, emphasize the role of multidisciplinary communication in patient care, and review a subcutaneous immunotherapy option for the adjuvant treatment of UC.